Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)
China flag China · Delayed Price · Currency is CNY
19.01
-0.54 (-2.76%)
Nov 17, 2026, 3:00 PM CST

SHA:688062 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
713.98658.69199.62127.6827.615.88
Other Revenue
3.823.820.160.150.130.35
717.8662.52199.78127.8427.7316.23
Revenue Growth
14.94%231.62%56.28%361.03%70.88%206.03%
Cost of Revenue
145.0675.7334.487.32.015.22
Gross Profit
572.74586.79165.3120.5325.7211
Selling, General & Admin
538.78493.83405.2368.36267.62189.16
Research & Development
952.47976.96782.87835.78758.61622.51
Other Operating Expenses
17.966.814.423.81.880.8
Operating Expenses
1,5181,4791,1931,2081,028812.44
Operating Income
-945.07-891.85-1,027-1,087-1,002-801.44
Interest Expense
-121.84-90.85-57.78-13.35-10.3-6.41
Interest & Investment Income
10.857.6120.9246.8845.757.38
Currency Exchange Gain (Loss)
-3.55-3.550.28-0.010.16-0.24
Other Non Operating Income (Expenses)
-13.573.29-6.22-1.74-1.822.63
EBT Excluding Unusual Items
-1,073-975.36-1,070-1,056-968.59-798.07
Gain (Loss) on Sale of Investments
-9.79-8.48-3.73-4.691.08-0.23
Gain (Loss) on Sale of Assets
0.540.1-0.11-0.010.332.06
Asset Writedown
7.75---3.56--
Other Unusual Items
18.4927.3426.388.619.0623.54
Pretax Income
-1,056-956.39-1,047-1,055-958.13-772.7
Income Tax Expense
-0.6715.86-0.913.52--
Earnings From Continuing Operations
-1,056-972.26-1,047-1,059-958.13-772.7
Minority Interest in Earnings
5.442.922.655.382.893.11
Net Income
-1,050-969.33-1,044-1,053-955.23-769.59
Net Income to Common
-1,050-969.33-1,044-1,053-955.23-769.59
Net Income Growth
------
Shares Outstanding (Basic)
418399400399391299
Shares Outstanding (Diluted)
418399400399391299
Shares Change
4.62%-0.27%0.24%1.93%30.74%5.32%
EPS (Basic)
-2.51-2.43-2.61-2.64-2.44-2.57
EPS (Diluted)
-2.51-2.43-2.61-2.64-2.44-2.57
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-1,039-447.93-1,287-1,283-1,264-639.91
Free Cash Flow Per Share
-2.48-1.12-3.22-3.21-3.23-2.14
Gross Margin
79.79%88.57%82.74%94.29%92.75%67.81%
Operating Margin
-131.66%-134.62%-514.17%-850.65%-3615.06%-4939.16%
Profit Margin
-146.29%-146.31%-522.53%-824.05%-3445.00%-4742.85%
Free Cash Flow Margin
-144.69%-67.61%-643.96%-1003.35%-4559.01%-3943.69%
EBITDA
-712.64-710.88-914.86-1,013-937.96-739.4
EBITDA Margin
-99.28%-107.30%----
D&A For EBITDA
232.43180.97112.3674.4364.4362.04
EBIT
-945.07-891.85-1,027-1,087-1,002-801.44
EBIT Margin
-131.66%-134.62%----
Revenue as Reported
717.8662.52199.78127.8427.7316.23